公开(公告)号：US20150307497A1

公开(公告)日：2015-10-29

申请号：US14443598

申请日：2013-11-18

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Shinkichi SUZUKI ,  Masami YAMADA ,  Makoto KAMATA ,  Takuto KOJIMA ,  Ikuo FUJIMORI ,  Kenichiro SHIMOKAWA

IPC: C07D487/04 ,  C07D405/14

CPC classification number: C07D487/04 ,  C07D209/46 ,  C07D401/06 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/14 ,  C07D519/00

Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa═ or —N═; X2 is —CRb═ or —N═; X3 is —CRc= or —N═; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.

Abstract translation: 提供具有胆碱能毒蕈碱M1受体阳性变构调节剂活性的化合物，可用作阿尔茨海默病，精神分裂症，疼痛，睡眠障碍等的预防或治疗药物。 本发明涉及由下式表示的化合物：其中环A是任选具有取代基的4-至7-元环; L是-O - ， - S - ， - SO-或-SO 2 - ; R1是任选具有取代基的C 1-6烷基（条件是当L是-O-，R 1不是被卤素原子任意取代的C 1-6烷基时）或任选具有取代基的环状基团 （s）; X1为-CRa =或-N =; X2为-CRb =或-N =; X3是-CRc =或-N=; R a，R b和R c各自为任选具有取代基的C 1-6烷基，C 2-6烯基，C 1-6烷氧基，C 3-6环烷基，C 3-6环烷氧基或C 6-14芳基， H或卤素，或其盐。

公开(公告)号：US20170121308A1

公开(公告)日：2017-05-04

申请号：US15318552

申请日：2015-06-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki OGINO ,  Eiji KIMURA ,  Shinkichi SUZUKI ,  Tomoko ASHIZAWA ,  Toshihiro IMAEDA ,  Ikuo FUJIMORI ,  Ryosuke ARAI

IPC: C07D401/10 ,  C07D213/81 ,  C07D405/14

CPC classification number: C07D401/10 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  C07D213/81 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

公开(公告)号：US20180155333A1

公开(公告)日：2018-06-07

申请号：US15568644

申请日：2016-04-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Taku KAMEI ,  Yasuyoshi ARIKAWA ,  Tomohiro OHASHI ,  Toshihiro IMAEDA ,  Ikuo FUJIMORI ,  Takashi MIKI ,  Jinichi YONEMORI ,  Yuya OGURO ,  Takahiro SUGIMOTO ,  Masaki SETO ,  Goushi NISHIDA ,  Makoto KAMATA ,  Hiroshi IMOTO

IPC: C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D409/14 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30

CPC classification number: C07D413/14 ,  A61K31/553 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07D409/14 ,  C07D413/04 ,  C07D417/14

Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20210139491A1

公开(公告)日：2021-05-13

申请号：US16622632

申请日：2018-06-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kazuaki TAKAMI ,  Masaki SETO ,  Shinobu SASAKI ,  Haruhi ANDO ,  Masaki OGINO ,  Tomoko OHASHI ,  Toshihiro IMAEDA ,  Ikuo FUJIMORI ,  Yasuhiro TSUKIMI ,  Masami YAMADA ,  Kenichiro SHIMOKAWA ,  Takeshi WAKABAYASHI ,  Masataka MURAKAMI ,  Makoto FUSHIMI ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Tomohiro OHASHI ,  Hideo SUZUKI ,  Hironobu MAEZAKI ,  Ayumu SATO ,  Yasutomi ASANO ,  Steve SWANN

IPC: C07D491/048 ,  A61K31/4355 ,  A61P1/10

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20170081332A1

公开(公告)日：2017-03-23

申请号：US15311025

申请日：2015-05-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro SUGIMOTO ,  Kenichiro SHIMOKAWA ,  Takuto KOJIMA ,  Hiroki SAKAMOTO ,  Ikuo FUJIMORI ,  Minoru NAKAMURA ,  Masami YAMADA ,  Masataka MURAKAMI ,  Makoto KAMATA ,  Shinkichi SUZUKI

IPC: C07D487/04 ,  C07D471/04

CPC classification number: C07D487/04 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/519 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH═ or —N═, or a salt thereof.